Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01202240 | Effect Of Ketoconazole On The Pharmacokinetics Of Tasocitinib (CP-690,550) In Healthy Volunteers | PHASE1 | COMPLETED | 12 | — | — | Sep 1, 2010 | Sep 1, 2010 | Feb 17, 2011 | 1 | Belgium |
| NCT01204112 | Estimate The Effect Of Repeat-Dose Rifampin On The Pharmacokinetics Of CP-690,550 In Healthy Volunteers | PHASE1 | COMPLETED | 12 | — | — | Sep 1, 2010 | Oct 1, 2010 | Oct 22, 2010 | 1 | United States |
| NCT01143805 | A Study To Estimate The Amount Of CP-690,550 (Study Drug) That Is Absorbed Into The Blood Of Healthy Subjects Following Oral Administration Of CP-690,550 In Tablet Form | PHASE1 | COMPLETED | 12 | — | — | Jul 1, 2010 | Aug 1, 2010 | Aug 10, 2010 | 1 | Singapore |
| Arm | Type | Description |
|---|---|---|
| Tasocitinib (CP-690,550) plus Ketoconazole | EXPERIMENTAL | - |
| Tasocitinib (CP-690,550) plus Rifampin | EXPERIMENTAL | - |
| Treatment A: Tasocitinib 10 mg oral tablet | EXPERIMENTAL | - |
| Treatment B: Tasocitinib 10 mg IV Infusion | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Tasocitinib (CP-690,55) plus Ketoconazole | DRUG | Period 1, Day 1: tasocitinib (CP-690,550) as a single oral 10 mg dose given as two 5 mg tablets Period 2, Days 1-2: ketoconazole as a daily single oral 400 mg (dose given as two 200 mg tablets Period 2, Day 3: ketoconazole as a single oral 400 mg dose given as two 200 mg tablets PLUS tasocitinib (CP-690,550) as a single oral 10 mg oral dose given as two 5 mg tablets Period 2, Day 4: No treatment (discharge) |
| Tasocitinib (CP-690,550) plus Rifampin | DRUG | Period 1, Day 1: Tasocitinib (CP-690,550) 30 mg (single oral dose) as six 5 mg tablets Period 2, Day 1-7: Rifampin 600 mg (single oral dose) q24h Period 2, Day 8: Tasocitinib (CP-690,550) 30 mg (single oral dose) as six 5 mg tablets Period 2, Day 9: No treatment (discharge) |
| Tasocitinib 10 mg oral tablet | DRUG | Treatment A: Single-dose of tasocitinib (CP-690,550) (10 mg) in the form of an oral tablet |
| Tasocitinib 10 mg IV Infusion | DRUG | Treatment B: Single-dose of tasocitinib (CP-690,550) (10 mg) in the form of a 30 minute intravenous infusion |
Inclusion Criteria: * Healthy male and/or female (non-childbearing potential) subjects between the ages of 18 and 55 years Exclusion Criteria: * Clinically significant disease * Recent history of serious infection